Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Phase 2 Terminated
1 enrolled
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
Phase 1/2 Terminated
5 enrolled
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
Phase 1/2 Terminated
25 enrolled
Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer
Phase 2 Terminated
13 enrolled 36 charts
Photodynamic Therapy-Induced Immune Modulation: Part III
Phase 1 Terminated
12 enrolled 9 charts
Perioperative Analgesia on Postoperative Opioid Usage and Pain Control in H&N Cancer Surgery
Phase 3 Terminated
30 enrolled
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Phase 1 Terminated
2 enrolled
Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
Phase 1/2 Terminated
15 enrolled 9 charts
Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery
Phase 2 Terminated
3 enrolled 6 charts
Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
Phase 1/2 Terminated
21 enrolled 11 charts
CHIP
Phase 3 Terminated
106 enrolled 10 charts
Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer
Phase 1 Terminated
6 enrolled
Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
Phase 1 Terminated
10 enrolled
Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum
Phase 1 Terminated
19 enrolled
Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas
Phase 1 Terminated
44 enrolled
Celecoxib/Oxaliplatin/Capecitabine for Gastric/Gastroesophageal Junction Carcinoma
Phase 2 Terminated
4 enrolled
Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases
Phase 2 Terminated
14 enrolled
S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women
Phase 2 Terminated
8 enrolled 5 charts
Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal
Phase 1 Terminated
41 enrolled
Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies
Phase 1 Terminated
21 enrolled 5 charts
ADAPT
Phase 2 Terminated
27 enrolled 10 charts
Pre-Prostatectomy Celecoxib or Placebo
Phase 2 Terminated
34 enrolled
Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer
Phase 2 Terminated
23 enrolled 8 charts
Celecoxib in Treating Women With Metastatic or Recurrent Breast Cancer
Phase 2 Terminated
39 enrolled
Neoadjuvant Celecoxib and Capecitabine Combined With Pelvic Irradiation in Treating Patients With Stage II or Stage III Adenocarcinoma (Cancer) of the Rectum
Phase 2 Terminated
3 enrolled
Preemptive Analgesia Following Uterine Artery Embolization
Phase 4 Terminated
23 enrolled 6 charts
Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs)
Phase 2 Terminated
8 enrolled 11 charts
Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer
Phase 2 Terminated
22 enrolled
Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma
Phase 2 Terminated
80 enrolled
Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy
Phase 2 Terminated
6 enrolled
Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT
Phase 2 Terminated
35 enrolled 12 charts
A Study of High-Risk Oral Cavity Cancer
Phase 2/3 Terminated
150 enrolled
A Study of Irinotecan, Cisplatin and Celebrex in Patients With Metastatic or Unresectable Esophageal Cancer
Phase 2 Terminated
6 enrolled
Paclitaxel and Celecoxib in Treating Patients With Recurrent or Persistent Platinum-Resistant Ovarian Epithelial or Primary Peritoneal Cancer
Phase 2 Terminated
Celecoxib in Treating Patients With Early-Stage Rectal Cancer
Phase NA Terminated
10 enrolled
Celecoxib in Preventing Polyps in Patients Who Have Undergone Surgery for Stage I Colon Cancer
Phase 3 Terminated
18 enrolled
Celecoxib as Adjuvant Biologic Therapy in Patients With Head and Neck and Lung Cancer
Phase 2 Terminated
1 enrolled 2 charts
Celebrex (Celecoxib) Treatment of Laryngeal Papilloma
Phase 2 Terminated
10 enrolled 6 charts
Celecoxib in Treating Patients With Relapsed Prostate Cancer Following Radiation Therapy or Radical Prostatectomy
Phase 2 Terminated
37 enrolled
A Pilot Study of Celecoxib in Patients With Grade 2 or 3 Uterine Cancers
Phase 2 Terminated
23 enrolled
Letrozole and Celecoxib in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
Phase 2 Terminated
For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy
Phase 2 Terminated
212 enrolled